Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited. This study aims to determine hepatitis B surface antigen (HBsAg) screening rates, HBV prevalence, and the rate of significant hepatitis caused by HBVr in SOM patients undergoing CMT. Methods: Based on the Oncology unit’s registration database from 2009–2013, we retrospectively reviewed records of all SOM patients ≥18 years undergoing CMT at Songklanagarind Hospital who were followed until death or ≥6 months after CMT sessions. Exclusion criteria included patients without baseline liver function tests (LFTs) and who underwent CMT before the study period. We obtained and analyzed baseline clinical characteristics, HBsAg screening, and LFT data during follow-up. Results: Of 3,231 cases in the database, 810 were eligible. The overall HBsAg screening rate in the 5-year period was 27.7%. Screening rates were low from 2009–2012 (7.8–21%) and increased in 2013 to 82.9%. The prevalence of HBV among screened patients was 7.1%. Of those, 75% underwent prophylactic antiviral therapy. During the 6-month followup period, there were three cases of significant hepatitis caused by HBVr (4.2% of all significant hepatitis cases); all were in the unscreened group. Conclusions: The prevalence of HBV in SOM patients undergoing CMT in our study was similar to the estimated prevalence in general Thai population, but the screening rate was quite low. Cases of HBVr causing significant hepatitis occurred in the unscreened group; therefore, HBV screening and treatment in SOM patients should be considered in HBV-endemic areas.
Abstract
Background/Aims: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited. This study aims to determine hepatitis B surface antigen (HBsAg) screening rates, HBV prevalence, and the rate of significant hepatitis caused by HBVr in SOM patients undergoing CMT. Methods: Based on the Oncology unit’s registration database from 2009–2013, we retrospectively reviewed records of all SOM patients ≥18 years undergoing CMT at Songklanagarind Hospital who were followed until death or ≥6 months after CMT sessions. Exclusion criteria included patients without baseline liver function tests (LFTs) and who underwent CMT before the study period. We obtained and analyzed baseline clinical characteristics, HBsAg screening, and LFT data during follow-up. Results: Of 3,231 cases in the database, 810 were eligible. The overall HBsAg screening rate in the 5-year period was 27.7%. Screening rates were low from 2009–2012 (7.8–21%) and increased in 2013 to 82.9%. The prevalence of HBV among screened patients was 7.1%. Of those, 75% underwent prophylactic antiviral therapy. During the 6-month followup period, there were three cases of significant hepatitis caused by HBVr (4.2% of all significant hepatitis cases); all were in the unscreened group. Conclusions: The prevalence of HBV in SOM patients undergoing CMT in our study was similar to the estimated prevalence in general Thai population, but the screening rate was quite low. Cases of HBVr causing significant hepatitis occurred in the unscreened group; therefore, HBV screening and treatment in SOM patients should be considered in HBV-endemic areas.
참고문헌 (24)
- Ott JJ, "Global epidemiology of hepatitis B virus infection : new estimates of age-specific HBsAg seroprevalence and endemicity", Vaccine, 30, pp.2212~2219 (2012)
- Hwang JP, "Management of patients with hepatitis B who require immunosuppressive therapy", Nat Rev Gastroenterol Hepatol, 11, pp.209~219 (2014)
- Lok AS, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study", Gastroenterology, 100, pp.182~188 (1991)
- Dong HJ, "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis", J Clin Virol, 57, pp.209~214 (2013)
- Mozessohn L, "Hepatitis B reactivation in HBsAg-negative", HBcAb-positive patients receiving rituximab for lymphoma : a meta-analysis, 2015, pp.22, 842~849
- Kim SJ, "Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group", Eur J Cancer, 49, pp.3486~3496 (2013)
- Hsu C, "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection : a prospective study", Hepatology, 59, pp.2092~2100 (2014)
- Zurawska U, "Hepatitis B virus screening before chemotherapy for lymphoma : a cost-effectiveness analysis", J Clin Oncol, 30, pp.3167~3173 (2012)
- Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
- Hsu C, "A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma : a randomized trial", Hepatology, 47, pp.844~853 (2008)
- Li H, "Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy : a systematic review and metaanalysis", Clin Res Hepatol Gastroenterol, 39, pp.80~92 (2015)
- Yeo W, "Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy : a prospective study", J Med Virol, 70, pp.553~561 (2003)
- Yeo W, "Comprehensive analysis of risk factors associating with Hepatitis B virus(HBV)reactivation in cancer patients undergoing cytotoxic chemotherapy", Br J Cancer, 90, pp.1306~1311 (2004)
- Paul S, "Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy : a systematic review and meta-analysis", Ann Intern Med, 164, pp.30~40 (2016)
- Artz AS, "American Society of Clinical Oncology provisional clinical opinion : chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases", J Clin Oncol, 28, pp.3199~3202 (2010)
- Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy : a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
- Hwang JP, "Hepatitis B virus management to prevent reactivation after chemotherapy : a review", Support Care Cancer, 20, pp.2999~3008 (2012)
- Brasseur M, "Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors", BMC Cancer, 15, pp.999~ (2015)
- Wi CI, "Low level of hepatitis B virus screening among patients receiving chemotherapy", Clin Gastroenterol Hepatol, 13, pp.970~975 (2015)[DOI]
- Hwang JP, "Low rates of hepatitis B virus screening at the onset of chemotherapy", J Oncol Pract, 8, pp.e32~ (2012)[DOI]
- Ikeda M, "Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan", Int J Clin Oncol, 21, pp.1162~1166 (2016)